Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$218.25M+2711.41%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Charles K. Gayer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 435
- Beta
- 0.56
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -3.71
Financials
Revenue
$218.25M+2711.4%Net Income
$78.39MEBITDA
$98.78MFree Cash Flow
$104.13MEPS (diluted)
$0.30Shares Outstanding (diluted)
265.17M+259.6%Operating Expenses
$115.94MCash & Debt
$352.57MReturn of Capital
$0.00Revenue by Segment (annual)
$874.84MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $874.84M | $263.86M | $1.26 |
| 2024 | $450.71M | $-88.88M | $-0.43 |
| 2023 | $331.41M | $-226.54M | $-1.18 |
| 2022 | $270.83M | $-247.12M | $-1.33 |
| 2021 | $157.17M | $-184.06M | $-1.03 |
| 2020 | $17.81M | $-182.81M | $-1.09 |
| 2019 | $48.84M | $-108.90M | $-0.94 |
| 2018 | $20.65M | $-101.25M | $-0.98 |
| 2017 | $25.19M | $-65.78M | $-0.78 |
| 2016 | $26.35M | $-55.14M | $-0.75 |
| 2015 | $48.26M | $-43.02M | $-0.59 |
| 2014 | $13.61M | $-45.19M | $-0.68 |
| 2013 | $17.33M | $-30.11M | $-0.55 |
| 2012 | $26.29M | $-39.08M | $-0.79 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.85
- Implied price
- $11.08
- Return from $8.17
- 6.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5.51 — -32.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 2 | 4 | 6 | 8 | 10 |
|---|---|---|---|---|---|
| -2.0% | -22.6% | -11.1% | -3.6% | 2.2% | 6.8% |
| 3.0% | -18.6% | -6.5% | 1.4% | 7.4% | 12.3% |
| 8.0% | -14.7% | -2.0% | 6.3% | 12.6% | 17.7% |
| 13.0% | -10.7% | 2.5% | 11.2% | 17.8% | 23.2% |
| 18.0% | -6.8% | 7.1% | 16.1% | 23.0% | 28.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
20-86.67%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·1d ago·Negative
…a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development.
View source ↗ - Newsschaeffersresearch.com·14d ago·Neutral
Biopharma Stock With Layers of Technical Support in Place After its most recent pullback, biopharmaceutical stock BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) bounced off the $8 level and has now reclaimed the 320-day moving average -- both of which have been key lines of pressure and support.
View source ↗ - Newsmarketbeat.com·17d ago·Negative
BioCryst Eyes $1B Rare-Disease Future Through External Innovation BioCryst Pharmaceuticals NASDAQ: BCRX is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·24d ago·Negative
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
BioCryst to Present at Upcoming Investor Conference RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.
View source ↗ - Newszacks.com·35d ago·Negative
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year? Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
View source ↗ - Newszacks.com·38d ago·Neutral
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newscnbc.com·39d ago·Negative
BioCryst is profitable. Now it wants to buy more rare disease drugs BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly stepping in to develop and acquire rare disease drugs.
View source ↗ - Newszacks.com·55d ago·Neutral
Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options Investors need to pay close attention to BCRX stock based on the movements in the options market lately.
View source ↗ - News247wallst.com·56d ago·Neutral
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst? BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a market cap of roughly $2.5 billion.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $0.10 per share
Typical surprise -14.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.30 vs $0.15beat
- Wed, May 6$-2.98 vs $0.06miss
- Thu, Feb 26$1.12 vs $0.07beat
- Mon, Nov 3$0.06 vs $0.07miss
- Mon, Aug 4$0.02 vs $0.03miss
- Mon, May 5$0.00 vs $-0.07beat
Estimates and results for BCRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BCRX officers and directors.
- Bought
- —
- Sold
- $4.7m
0 trades
11 trades
- Mckee Amy Esold
- Barnes Alane Psold
- Heggie Theresasold
- Barnes Alane Psold
- Barnes Alane Psold
- Barnes Alane Psold
- Barnes Alane Psold
- Barnes Alane Psold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 7, 2026 (59d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2025 (32d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 11, 2023 (26d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.